Hope on the Horizon: Early Data from AGTC's XLRP Gene Therapy Trial
For individuals and families affected by inherited retinal diseases (IRDs), particularly X-linked retinitis pigmentosa (XLRP), news of progress in gene therapy research offers a beacon of hope. Applied Genetic Technologies Corporation (AGTC) recently announced encouraging data from its ongoing Phase 1/2 clinical trial for a gene therapy targeting XLRP, a condition that leads to progressive vision loss and often legal blindness by middle age. This update, reported by drugdiscoverytrends.com, provides an early look at the potential of this investigational treatment.
XLRP is a severe inherited retinal disease primarily affecting males, caused by mutations in the RPGR gene. It results in the degeneration of photoreceptor cells, leading to symptoms like night blindness, progressive constriction of the visual field, and eventual central vision loss. The development of therapies for XLRP is crucial for the IRD community, offering the possibility of slowing or halting disease progression and preserving vision.
According to AGTC's announcement, the ongoing Phase 1/2 clinical trial is evaluating a gene therapy designed to deliver a functional copy of the RPGR gene to retinal cells. Data from the trial's Groups 5 and 6, specifically for patients who met the inclusion criteria for subsequent Phase 2 and Phase 2/3 trials (Skyline and Vista, respectively), showed positive responses. Four out of eight patients in these groups demonstrated an improvement in retinal sensitivity at 12 months, as measured by microperimetry. Responders were defined as those with an improvement of at least 7 decibels in retinal sensitivity at five or more points in the central retina. Additionally, data on best-corrected visual acuity continued to suggest a biological response at the 12-month mark. Preliminary evidence from a subset of Group 4 patients also indicated continued durable responses at 24 months.
What does this mean for patients and families? While these are early-stage results from an ongoing trial, they indicate that the gene therapy is showing signs of biological activity and potential benefit in some patients. The improvements in retinal sensitivity are particularly noteworthy, as they suggest a positive impact on the function of the retina. This progress supports the continued development of this gene therapy, moving it closer to potentially becoming a viable treatment option. AGTC's President and CEO, Sue Washer, stated that a growing body of data supports the